These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33828378)

  • 1. Assessing Adherence and Persistence to Non-vitamin K Antagonist Oral Anticoagulants (NOACs) among Patients with Atrial Fibrillation in Tertiary-care Referral Centers in Malaysia.
    Kubas MA; Shabaruddin FH; Mazlan-Kepli W; Jagan N; Mohamed S; Mohamed Nazar NI; Zin CS
    J Pharm Bioallied Sci; 2020 Nov; 12(Suppl 2):S781-S786. PubMed ID: 33828378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world adherence to oral anticoagulants in atrial fibrillation].
    Simonyi G; Paksy A; Várnai R; Medvegy M
    Orv Hetil; 2020 May; 161(20):839-845. PubMed ID: 32364687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and persistence to oral anticoagulants in patients with atrial fibrillation: A Belgian nationwide cohort study.
    Grymonprez M; Capiau A; Steurbaut S; Mehuys E; Boussery K; De Backer TL; Lahousse L
    Front Cardiovasc Med; 2022; 9():994085. PubMed ID: 36247477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation.
    Patti G; Wang R; Marston XL; Yeh YC; Zimmermann L; Ye X; Gao X; Brüggenjürgen B
    Cardiol Ther; 2023 Jun; 12(2):371-391. PubMed ID: 37138193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.
    Komen JJ; Pottegård A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hellfritzsch M; Hallas J; Olesen M; Bennie M; Mueller T; Voss A; Schink T; Haug U; Kollhorst B; Karlstad Ø; Kjerpeseth LJ; Klungel OH
    Europace; 2021 Nov; 23(11):1722-1730. PubMed ID: 34096584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
    Forslund T; Wettermark B; Hjemdahl P
    Eur J Clin Pharmacol; 2016 Mar; 72(3):329-38. PubMed ID: 26613954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
    Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
    Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
    Maura G; Pariente A; Alla F; Billionnet C
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1367-1377. PubMed ID: 28752560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
    Kim H; Lee YS; Kim TH; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Shim J; Uhm JS; Park HW; Choi EK; Kim JB; Kim C; Kim J; Joung B
    Korean J Intern Med; 2020 Jan; 35(1):99-108. PubMed ID: 31014064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study.
    Banerjee A; Benedetto V; Gichuru P; Burnell J; Antoniou S; Schilling RJ; Strain WD; Ryan R; Watkins C; Marshall T; Sutton CJ
    Heart; 2020 Jan; 106(2):119-126. PubMed ID: 31601729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.